Results 81 to 90 of about 121,829 (241)
Tạp chí Khoa học và Công nghệỞ nghiên cứu này, nhóm tác giả đã tiến hành khảo sát sự thay đổi về hiệu suất và các đặc tính của N-CNTs như hình thái bề mặt, giá trị BET, độ ổn định oxy hóa theo nhiệt độ tổng hợp và thể tích NH4OH.
Lê Đức Ngưu +2 more
doaj
Potential therapeutic targeting of BKCa channels in glioblastoma treatment
Molecular Oncology, EarlyView.This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak +4 more
wiley +1 more source
Molecular Oncology, EarlyView.The LINC01116 long noncoding RNA is induced by hypoxia and associated with poor prognosis and high recurrence rates in two cohorts of lung adenocarcinoma patients. Here, we demonstrate that besides its expression in cancer cells, LINC01116 is markedly expressed in lymphatic endothelial cells of the tumor stroma in which it participates in hypoxia ...
Marine Gautier‐Isola +12 more
wiley +1 more source
Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma
Molecular Oncology, EarlyView.Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken +7 more
wiley +1 more source
A Novel Method for Preparation of Alumina-Supported Rhenium-Cesium Catalyst, Re-Cs/-Al2O3 [PDF]
Iranian Journal of Chemistry & Chemical Engineering, 2008 Alumina-supported Cs3[Re(C2O4)3] precursor has been synthesized for preparation of Re-Cs/g-Al2O3 catalyst. Cs3[Re(C2O4)3] has been prepared from the reaction of ReCl3 with H2C2O4.2H2O and CsCl in water.
Hassan Hadadzadeh +3 more
doaj
Molecular Oncology, EarlyView.Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon +13 more
wiley +1 more source
Adsorption of Bovine Serum Albumin onto Hydroxylapatite: Theoretical Modeling and Measurements [PDF]
Iranian Journal of Chemistry & Chemical Engineering, 2010 Adsorption of Bovine Serum Albumin (BSA) onto calcium Hydroxyl Apatite (HA), Ca10PO4(OH)2, has been studied by Ultra Violet (UV) spectroscopy. The adsorption isotherms of BSA onto the HA surface at 291.7 K and 303.2 K were satisfactorily presented by ...
Hamid Modarress, Leila Allafkari
doaj
LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro
Molecular Oncology, EarlyView.Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix +13 more
wiley +1 more source
Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin
Molecular Oncology, EarlyView.The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla +10 more
wiley +1 more source
Molecular Oncology, EarlyView.We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala +15 more
wiley +1 more source